Advertisement

Topics

Ascendis Pharma’s Phase 3 Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon hGH to a Daily Growth Hormone

11:20 EDT 26 Mar 2019 | Speciality Pharma Journal

COPENHAGEN, Denmark, March 24, 2019 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address unmet medical needs, today announced top-line results from its pivotal phase 3 heiGHt Trial were presented at the Endocrine Society’s annual meeting, ENDO 2019, in New Orleans. Trial results demonstrated that …

Original Article: Ascendis Pharma’s Phase 3 Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon hGH to a Daily Growth Hormone

NEXT ARTICLE

More From BioPortfolio on "Ascendis Pharma’s Phase 3 Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon hGH to a Daily Growth Hormone"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...